ClinicalTrials.gg
RecruitingNCT06644781Updated Oct 26, 2026

A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

A Phase 3 interventional study of Ifinatamab deruxtecan and Docetaxel in Esophageal Squamous Cell Carcinoma, sponsored by Daiichi Sankyo. Recruiting at 168 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Daiichi Sankyo · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.
Updated Oct 26, 202638 sites added2 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
510
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 401 studies in Esophageal Squamous Cell Carcinoma with a site in China — 174 open to participants now, 213 under way, 32 of them phase 3. Esophageal Squamous Cell Carcinoma · China.

Planned enrollment
27th of 351
510 · median 70
Started
2025
with 30 others
Phase 3
52 of 401
20 open now
Primary completion
2028-06
later than 178 of 212 live
Registered
298th of 401
by date

Among the 401 studies in Esophageal Squamous Cell Carcinoma with a site in China, this one is the 27th largest by planned enrollment of the 351 interventional ones that give a count, is one of 31 that started in 2025, is one of 52 in phase 3, reaches primary completion later than 178 of the 212 other live ones, and was the 298th registered.

Esophageal Squamous Cell Carcinoma

678 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 269 are open to participants now.

Browse Esophageal Squamous Cell Carcinoma studies →

Open to participants now

174 of the 401 studies in Esophageal Squamous Cell Carcinoma with a site in China are open now. Recruiting first, the newest first:

169 more — sign in →

All 174 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 401 studies in Esophageal Squamous Cell Carcinoma with a site in China, or all of them as a file.
02

Study summary

This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd) in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have experienced disease progression following treatment with a platinum-based systemic therapy and an immune checkpoint inhibitor (ICI) compared with investigator's choice of chemotherapy (ICC).

Read the detailed description

The primary objective of this study is to evaluate the overall survival (OS) benefit of I-DXd compared with investigator's choice of chemotherapy (ICC).

The key secondary objectives of the study will evaluate the progression-free survival (PFS) and objective response rate (ORR) benefit of I-DXd compared with ICC.

03

Conditions studied

  • Esophageal Squamous Cell Carcinoma

Keywords

  • Esophageal squamous cell carcinoma
  • Ifinatamab deruxtecan (I-DXd)
  • DS-7300a
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet all of the following criteria to be eligible for randomization into the study:

  1. Participants aged ≥18 years (follow local regulatory requirements if the legal age of consent for study participation is >18 years old).
  2. Has or cytologically documented unresectable locally advanced or ESCC according to American Joint Committee on Cancer 8th edition staging system on ESCC.
  3. Has disease progression post a platinum-based chemotherapy and an ICI treatment per global or local guidelines, with a maximum of 1 for unresectable advanced or metastatic ESCC.
  4. The participant must provide adequate baseline tumor samples with sufficient quantity and quality of tumor tissue content as defined in the Laboratory Manual.
  5. Has at least 1 on computed tomography (CT)/magnetic resonance imaging (MRI) according to v1.1 as assessed by the investigator. Measurable lesions should not be from a previously irradiated site. If the lesion at a previously irradiated site is the only selectable target lesion, a radiological assessment showing significant progression of the irradiated lesion should be provided by the investigator.
  6. Has an PS of 0 or 1 within 7 days prior to Cycle 1 Day 1.

Exclusion criteria

Exclusion Criteria:

Participants who meet any of the following criteria will be disqualified from entering the study:

  1. Has received prior treatment with orlotamab, enoblituzumab, or other B7-H3 targeted agents, including I-DXd.
  2. Has received any topoisomerase inhibitor.
  3. Has or cytologically confirmed adenosquamous carcinoma subtype.
  4. Is ineligible to all the chemotherapies in the comparator arm due to prior progression or intolerance.
  5. Has tumor invasion into organs located adjacent to the esophageal disease site (eg, aorta or respiratory tract) at an increased risk of bleeding or fistula as assessed by the investigator.
  6. Clinically active , spinal cord compression, or , defined as untreated or symptomatic, or requiring therapy with or anticonvulsants to control associated symptoms. Subjects with clinically inactive or treated brain metastases who are asymptomatic (ie, without neurologic signs or symptoms and not requiring treatment with corticosteroids or anticonvulsants) may be included in the study. Subjects must have a stable neurologic status and discontinue corticosteroid usage for at least 2 weeks prior to Screening.
  7. Has any of the following within the past 6 months: cerebrovascular accident, , other arterial thromboembolic event, or pulmonary embolism.
  8. Has a corneal disease.
  9. Has a history of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required corticosteroids, current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at Screening.
  10. Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses, including, but not limited to, any underlying pulmonary disorder (ie, pulmonary emboli within 3 months of the study randomization, severe asthma, [COPD], restrictive lung disease, pleural effusion, etc), and potential pulmonary involvement caused by any , connective tissue, or inflammatory disorders (eg, rheumatoid arthritis, Sjögren's syndrome, sarcoidosis, etc), prior pneumonectomy, or requirement for supplemental oxygen.
  11. Is on chronic steroid treatment (dose of 10 mg daily or more prednisone equivalent), except for low-dose inhaled steroids (for asthma/COPD), topical steroids (for mild skin conditions), or intra-articular steroid injections.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
510 participants (estimated)

Study arms

  • Experimental
    I-DXd

    Participants who are randomized to receive an intravenous infusion of I-DXd 12 mg/kg on Day 1 of every 21-day cycle (Q3W).

    Drug: Ifinatamab deruxtecan

  • Active comparator
    Investigator's Choice of Chemotherapy (ICC)

    Participants who are randomized to receive an intravenous infusion of investigator's choice of chemotherapy (docetaxel, paclitaxel, and irinotecan HCl).

    Drug: Docetaxel · Drug: Paclitaxel · Drug: Irinotecan hydrochloride (HCl)

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Overall Survival (OS) is defined as the time interval from the date of randomization to the date of death due to any cause.

    Time frame: From the date of randomization to the date of death due to any cause, up to approximately 54 months

Secondary outcomes

  1. Progression-free survival (PFS)

    Progression-free survival (PFS) is defined as the time interval from the date of randomization to the first date of disease progression as determined by blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or death due to any cause, whichever occurs first.

    Time frame: From the date of randomization to the date of disease progression or death due to any cause, whichever occurs first, up to approximately 54 months

  2. Objective Response Rate (ORR)

    Objective response rate (ORR) is defined as the proportion of subjects with a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) as assessed by BICR per RECIST v1.1.

    Time frame: From the time of first dose of study drug until date of documented disease progression or death, whichever occurs first, up to approximately 54 months

  3. Duration of Response (DoR)

    Duration of response (DoR) is defined as the time from the date of first documentation of objective tumor response (CR or PR), which is subsequently confirmed by BICR assessment, to the first documentation of objective tumor progression (confirmed by BICR) or to death due to any cause, whichever occurs first.

    Time frame: From the time of the first dose of study drug until the date of documented disease progression (as assessed by BICR) or death due to any cause, up to approximately 54 months

  4. Disease Control Rate (DCR)

    Disease control rate (DCR) is defined as the proportion of participants with a BOR of confirmed CR, confirmed PR, or stable disease (SD) according to RECIST v1.1 and will be determined by BICR assessment review of tumor scans.

    Time frame: From the time of the first dose of study drug until the date of documented disease progression (as assessed by BICR) or death due to any cause, up to approximately 54 months

  5. Change from baseline in European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire Score (EORTC QLQ-C30)

    Time frame: Baseline up to 54 months

  6. Change from baseline in European Organisation for Research and Treatment of Cancer Esophageal Cancer Module Score (EORTC OES18)

    Time frame: Baseline up to 54 months

  7. Incidence of Treatment-emergent Adverse Events (TEAEs), Serious TEAEs, and Adverse Events of Special Interest (AESIs)

    A TEAE is defined as an adverse event (AE) with a start or worsening date during the on-treatment period. A serious TEAE is defined as any untoward medical occurrence that at any dose results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is an important medical event, or may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes noted. AESIs will also be assessed. AEs will be coded using MedDRA and will be graded using NCI-CTCAE v5.0.

    Time frame: Baseline up to 54 months

  8. Percentage of Participants Who Have Treatment-emergent ADA

    Anti-drug antibodies (ADAs) will be measured in the plasma using a validated assay.

    Time frame: Baseline up to 54 months

  9. Pharmacokinetic Parameter Time to Maximum Concentration (Tmax) for I-DXd

    Plasma pharmacokinetic parameters will be assessed using noncompartmental methods.

    Time frame: Cycle 1: Before infusion (BI), end of infusion (EOI), 3 hours (hr), 6hr, 24hr, 72hr, 168hr, 336hr, 504hr postdose; Cycle 2: BI and EOI; Cycle 3: BI, EOI, and 6hr postdose; Cycle 4, 5, & every 2 cycles thereafter, up to 54 mths: BI (each cycle is 21 days)

  10. Pharmacokinetic Parameter Time to Maximum Concentration (Tmax) for Total Anti-B7-H3 Antibody

    Plasma pharmacokinetic parameters will be assessed using noncompartmental methods.

    Time frame: Cycle 1: Before infusion (BI), end of infusion (EOI), 3 hours (hr), 6hr, 24hr, 72hr, 168hr, 336hr, 504hr postdose; Cycle 2: BI and EOI; Cycle 3: BI, EOI, and 6hr postdose; Cycle 4, 5, & every 2 cycles thereafter, up to 49 mths: BI (each cycle is 21 days)

  11. Pharmacokinetic Parameter Time to Maximum Concentration (Tmax) for MAAA-1181a

    Plasma pharmacokinetic parameters will be assessed using noncompartmental methods.

    Time frame: Cycle 1: Before infusion (BI), end of infusion (EOI), 3 hours (hr), 6hr, 24hr, 72hr, 168hr, 336hr, 504hr postdose; Cycle 2: BI and EOI; Cycle 3: BI, EOI, and 6hr postdose; Cycle 4, 5, & every 2 cycles thereafter, up to 49 mths: BI (each cycle is 21 days)

07

Study locations

167 of 168 sites recruiting

Showing the first 100 of 168 sites across 17 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) on completed studies and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Completed studies that has reached a global end or completion with all data set collected and analyzed, and for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents on completed clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Jun 2028, 38 months after the start.

Of 44 phase 3 interventional studies under Esophageal Squamous Cell Carcinoma, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 76. This study's planned 38 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2024
First posted
Oct 16, 2024
StartActual
Mar 27, 2025
Primary completionEst.
Jun 1, 2028
CompletionEst.
Nov 1, 2029
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
38 sites added, 2 sites removed
Show 38 added (10 China, 9 France, 6 Italy, 3 Spain, 3 United Kingdom, 2 Romania, 1 United States, 1 Belgium, 1 Japan, 1 Netherlands, 1 Norway)
  • USC Norris Comprehensive Cancer Center · Los Angeles, United States
  • Universitair Ziekenhuis Gent · Ghent, Belgium
  • The First Hospital of Jilin University · Changchun, China
  • The First Affiliated Hospital Zhejiang University School of Medicine · Hangzhou, China
  • Zhejiang Cancer Hospital · Hangzhou, China
  • Anhui Provincial Cancer Hospital · Hefei, China
  • The Second Hospital of Anhui Medical University · Hefei, China
  • Jieyang Peoples Hospital · Jieyang, China
  • Linyi Cancer Hospital · Linyi, China
  • The First Affiliated Hospital of Henan University of Science and Technology · Luoyang, China
  • Cancer Hospital of Shantou University Medical College · Shantou, China
  • Henan Cancer Hospital · Zhengzhou, China
  • Hopital Claude Huriez - Chu Lille · Lille, France
  • Centre Leon Berard · Lyon, France
  • Institut Paoli Calmettes · Marseille, France
  • Chru De Nantes Hotel-Dieu · Nantes, France
  • Centre Antoine Lacassagne · Nice, France
  • Hăpital Saint-Antoine · Paris, France
  • Chu Bordeaux - Hăpital Haut-Lăvăque · Pessac, France
  • Institut Curie - Centre Renă Huguenin · Saint-Cloud, France
  • Institut de Cancărologie de Strasbourg Europe - Icans · Strasbourg, France
  • Clinica Oncologica-AOU delle Marche second floor · Ancona, Italy
  • National Institute of Gastroenterology Saverio De Bellis Research Hospital · Castellana Grotte, Italy
  • IRCCS Ospedale Policlinico San Martino · Genova, Italy
  • IRCCS Ospedale San Raffaele · Milan, Italy
  • Azienda Ospedaliero Universitaria Pisana · Pisa, Italy
  • A.O. Pia Fondazione Cardinale G. Panico · Tricase, Italy
  • Nho Shikoku Cancer Center · Matsuyama, Japan
  • Radboud University Medical Center · Nijmegen, Netherlands
  • Sørlandet Sykehus Hf Kristiansand · Kristiansand, Norway
  • …and 8 more on the registry record
Show 2 removed
  • Unité de recherche clinique ICANS · Strasbourg, France
  • Shikoku Cancer Center · Matsuyama, Japan
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    38 sites added, 2 sites removed
    Show 38 added (10 China, 9 France, 6 Italy, 3 Spain, 3 United Kingdom, 2 Romania, 1 United States, 1 Belgium, 1 Japan, 1 Netherlands, 1 Norway)
    • USC Norris Comprehensive Cancer Center · Los Angeles, United States
    • Universitair Ziekenhuis Gent · Ghent, Belgium
    • The First Hospital of Jilin University · Changchun, China
    • The First Affiliated Hospital Zhejiang University School of Medicine · Hangzhou, China
    • Zhejiang Cancer Hospital · Hangzhou, China
    • Anhui Provincial Cancer Hospital · Hefei, China
    • The Second Hospital of Anhui Medical University · Hefei, China
    • Jieyang Peoples Hospital · Jieyang, China
    • Linyi Cancer Hospital · Linyi, China
    • The First Affiliated Hospital of Henan University of Science and Technology · Luoyang, China
    • Cancer Hospital of Shantou University Medical College · Shantou, China
    • Henan Cancer Hospital · Zhengzhou, China
    • Hopital Claude Huriez - Chu Lille · Lille, France
    • Centre Leon Berard · Lyon, France
    • Institut Paoli Calmettes · Marseille, France
    • Chru De Nantes Hotel-Dieu · Nantes, France
    • Centre Antoine Lacassagne · Nice, France
    • Hăpital Saint-Antoine · Paris, France
    • Chu Bordeaux - Hăpital Haut-Lăvăque · Pessac, France
    • Institut Curie - Centre Renă Huguenin · Saint-Cloud, France
    • Institut de Cancărologie de Strasbourg Europe - Icans · Strasbourg, France
    • Clinica Oncologica-AOU delle Marche second floor · Ancona, Italy
    • National Institute of Gastroenterology Saverio De Bellis Research Hospital · Castellana Grotte, Italy
    • IRCCS Ospedale Policlinico San Martino · Genova, Italy
    • IRCCS Ospedale San Raffaele · Milan, Italy
    • Azienda Ospedaliero Universitaria Pisana · Pisa, Italy
    • A.O. Pia Fondazione Cardinale G. Panico · Tricase, Italy
    • Nho Shikoku Cancer Center · Matsuyama, Japan
    • Radboud University Medical Center · Nijmegen, Netherlands
    • Sørlandet Sykehus Hf Kristiansand · Kristiansand, Norway
    • …and 8 more on the registry record
    Show 2 removed
    • Unité de recherche clinique ICANS · Strasbourg, France
    • Shikoku Cancer Center · Matsuyama, Japan
    + 1 other change: identifiers

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06644781
Lead sponsor
Daiichi Sankyo
Responsible party
Sponsor
First posted
Oct 16, 2024
Start date
Mar 27, 2025
Primary completion
Jun 1, 2028 (estimated)
Completion
Nov 1, 2029 (estimated)
Last update
Oct 26, 2026

Study contacts

Daiichi Sankyo Contact for Clinical Trial Information
Contact
CTRinfo_us@daiichisankyo.com
9089926400

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ifinatamab deruxtecan

Start the discussion